Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2016-03-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/910 |
| Summary: | During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway. |
|---|---|
| ISSN: | 2095-3941 2095-3941 |